PPA
RCKT icon

Parametric Portfolio Associates’s Rocket Pharmaceuticals RCKT Stock Holding History

Parametric Portfolio Associates’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$685K Buy
43,161
+7,340
+20% +$127K ﹤0.01% 2949
2021
Q4 		$782K Sell
35,821
-13,913
-28% -$380K ﹤0.01% 2885
2021
Q3 		$1.49M Sell
49,734
-11,463
-19% -$417K ﹤0.01% 2605
2021
Q2 		$2.71M Sell
61,197
-39,885
-39% -$1.73M ﹤0.01% 2264
2021
Q1 		$4.49M Buy
101,082
+55,007
+119% +$3.02M ﹤0.01% 2259
2020
Q4 		$2.53M Buy
46,075
+32,328
+235% +$1.18M ﹤0.01% 2514
2020
Q3 		$314K Sell
13,747
-96
-0.7% -$2.37K ﹤0.01% 3466
2020
Q2 		$290K Buy
13,843
+3,119
+29% +$56.2K ﹤0.01% 3485
2020
Q1 		$150K Sell
10,724
-13,338
-55% -$264K ﹤0.01% 3629
2019
Q4 		$548K Buy
24,062
+998
+4% +$16.7K ﹤0.01% 3340
2019
Q3 		$269K Buy
23,064
+10,659
+86% +$132K ﹤0.01% 3594
2019
Q2 		$186K Buy
+12,405
New +$216K ﹤0.01% 3756
2017
Q3 		– Sell
-7,045
Closed -$54K – 4047
2017
Q2 		$54K Sell
7,045
-107
-1% -$798 ﹤0.01% 3961
2017
Q1 		$57K Buy
+7,152
New +$48.1K ﹤0.01% 3732

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Parametric Portfolio Associates's RCKT Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Rocket Pharmaceuticals (RCKT) stake by 20% in Q1 2022, buying an estimated $127K and bringing the position to 43,161 shares worth $685K. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

Parametric Portfolio Associates first reported a position in RCKT in Q1 2017 and has held it in 14 quarters since. The position peaked at $4.49M in Q1 2021. 149 funds tracked by Wall St. Rank hold RCKT as of Q1 2022.

  • Parametric Portfolio Associates held 43,161 shares of Rocket Pharmaceuticals worth $685K as of Q1 2022.
  • Parametric Portfolio Associates bought 7,340 Rocket Pharmaceuticals shares in Q1 2022, an estimated $127K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2949 holding.
  • Parametric Portfolio Associates first reported a position in Rocket Pharmaceuticals in Q1 2017 and has held it in 14 quarters since.
  • Parametric Portfolio Associates's Rocket Pharmaceuticals position peaked at $4.49M in Q1 2021.
  • 149 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.